EUR/USD likely to find a peak near 1.25: UBS
Jim Brown, the CEO and President of USANA Health Sciences Inc . (NYSE:USNA), has recently sold a portion of his holdings in the company. According to a recent SEC filing, Brown disposed of 5,000 shares of common stock on March 3, 2025. The shares were sold at a price of $29.47 each, amounting to a total transaction value of $147,350. The sale comes as USANA’s stock has declined about 24% over the past six months, though InvestingPro analysis indicates the company maintains strong financial health with a current ratio of 2.0.
Following the sale, Brown retains ownership of 15,716 shares in the company. The transaction was executed directly by Brown, as indicated in the filing. USANA Health Sciences, headquartered in Salt Lake City, Utah, is known for its work in medicinal chemicals and botanical products. The company demonstrates solid fundamentals with impressive gross profit margins of 81% and trades at an attractive P/E ratio of 13.6, suggesting potential undervaluation according to InvestingPro’s Fair Value assessment.
In other recent news, USANA Health Sciences reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.64, exceeding the projected $0.49. The company also reported quarterly revenue of $214 million, surpassing the anticipated $208.84 million. Despite these positive results, USANA’s guidance for fiscal year 2025 left investors concerned, with projected earnings per share between $2.35 and $3.00, which fell short of the consensus estimate of $2.87. The revenue forecast for FY2025 is between $920 million and $1 billion, closely aligning with the consensus estimate of $934.5 million.
USANA’s acquisition of Hiya Health Products contributed minimally to the fourth-quarter results, but the company anticipates Hiya’s revenue to grow significantly in 2025. The acquisition aims to enhance USANA’s presence in the children’s health market. The company’s strategic focus for 2025 includes launching over 20 new products and reformulations, with a particular emphasis on supporting its Associate sales force. USANA has also announced plans to implement a new associate incentive program in the latter half of 2025 to enhance its direct selling model.
The company’s year-over-year financial performance showed challenges, with net sales for FY2024 down 7% to $855 million and net earnings dropping 34% to $42 million. USANA’s leadership acknowledged these challenges but expressed optimism about the company’s growth strategy. Analysts from firms like Sidoti and Company and D.A. Davidson have inquired about the company’s promotional strategies and revenue guidance by region, reflecting the ongoing interest and scrutiny from the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.